GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Buyback Yield %

Redhill Biopharma (Redhill Biopharma) Buyback Yield % : -85.81 (As of May. 16, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Redhill Biopharma's current buyback yield was -85.81%.


Redhill Biopharma Buyback Yield % Historical Data

The historical data trend for Redhill Biopharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Buyback Yield % Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.96 -7.69 -58.09 -182.07 -48.60

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -232.04 -242.53 136.23 -

Competitive Comparison of Redhill Biopharma's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Buyback Yield % falls into.



Redhill Biopharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Redhill Biopharma's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 13.959) / 28.724916
=-48.60%

Redhill Biopharma's annualized Buyback Yield for the quarter that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + -1.611) * 4 / 4.730352
=136.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Jun. 2023) data.


Redhill Biopharma Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.